ArticleCureus2025
Acetazolamide-Assisted Weaning From Mechanical Ventilation in a Child With Mixed Sleep Apnea: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An elevated central apnea-hypopnea index is typically considered indicative of abnormal breathing in children. Treatment of central sleep apnea (CSA) is complex, and multiple treatment options are tried with variable outcomes. Acetazolamide, a carbonic anhydrase inhibitor, is known to induce metabolic acidosis and can stimulate the respiratory drive. We report a 13-year-old boy who was having obesity and mixed apnea with an apnea-hypopnea index of 67.4/hour, who was hospitalized with hypercapnic respiratory failure. He was successfully weaned from prolonged mechanical ventilation following acetazolamide therapy. Post-discharge, he has had no apnea and continues to do well, with an improved quality of life at two months of follow-up. Acetazolamide use for central apnea/mixed apnea in children is very rare and not well established. Our case highlights the potential use of acetazolamide as an adjunct therapy in children with CSA, which needs further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.